Abstract
The mainstay of current management of patients with Alzheimer’s disease involves drugs that provide symptomatic therapy. Research approaches for future therapy of Alzheimer’s disease are focusing on disease modifying and/or preventive approaches. Two classes of medications have been approved by the US FDA for the treatment of Alzheimer’s disease: the cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine), mostly for mild to moderate Alzheimer’s disease, and the noncompetitive NMDA receptor antagonist memantine for the moderate to severe stages of Alzheimer’s disease.
Management of comorbid medical problems can be more complex in patients with dementia than in those without dementia. Unfortunately, medication adherence in Alzheimer’s disease is low and good adherence is essential for attempting to slow disease progression and improve or stabilize quality of life. Simplifying treatment regimens and providing more caregiver- and patient-friendly modes of administration that fit in better with daily routines can ease caregiver stress which, in turn, may have a favourable impact on the patient’s condition. To overcome problems of medication adherence in the elderly, simple, user-friendly dosage regimens should be prescribed for all medications; thus the need for novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease, such as once-daily done-pezil, memantine and galantamine, and transdermal rivastigmine
Similar content being viewed by others
References
Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003 Mar 4; 138(5): 400–10
Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003 Apr 3; 348(14): 1356–64
Hy LX, Keller DM. Prevalence of AD among whites: a summary by levels of severity. Neurology 2000 Jul 25; 55(2): 198–204
Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005 Dec 17; 366(9503): 2112–7
Kosasa T, Kuriya Y, Matsui K, et al. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer’s disease, on cholinesterase activity in rats. Eur J Pharmacol 2000; 389: 173–9
Yamada K, Takayanagi M, Kamei H, et al. Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res 2005; 162: 191–9
Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2: 1457–9
Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer’s disease. Drugs 2000 Nov; 60(5): 1095–122
Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer’s disease. Curr Drug Metab 2008 May; 9(4): 332–5
Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003 Jan 8; 289(2): 210–6
Bleich S, Romer K, Wiltfang J. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 2003; 18: S33–40
Danysz W, Parsons CG, Bresink I, et al. Glutamate in CNS disorders. Drug News Perspect 1995; 8: 261–77
Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18: S23–32
Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999; 38: 735–67
Brauner DJ, Muir JC, Sachs GA. Treating non dementia illnesses in patients with dementia. JAMA 2000 Jun 28; 283(24): 3230–5
Karlawish JH, Casarett DJ, James BD, et al. The ability of persons with Alzheimer disease (AD) to make a decision about taking an AD treatment. Neurology 2005 May 10; 64(9): 1514–9
Pruchno RA, Smyer MA, Rose MS, et al. Competence of long-term care residents to participate in decisions about their medical care: a brief, objective assessment. Gerontologist 1995 Oct; 35(5): 622–9
Morrison RS, Siu AL. Survival in end-stage dementia following acute illness. JAMA 2000 Jul 5; 284(1): 47–52
Singh G, Thomas SK, Arcona S, et al. Treatment persistency with rivastigmine and donepezil in a large state Medicare program. J Am Geriatr Soc 2005; 53: 1269–70
Small G, Dubois B. A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007 Nov; 23(11): 2705–13
Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995; 56Suppl. 1: 18–23
Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990; 150: 841–5
Alzheimer’s Association. Statistics about Alzheimer’s disease [online]. Available from URL: http://www.alz.org/AboutAD/statistics.asp [Accessed 2006 Sep 18]
Connell CM, Janevic MR, Gallant MP. The costs of caring: the impact of dementia on family caregivers. J Geriatr Psychiatry Neurol 2001; 14: 179–87
Delagarza VW. Pharmacologic treatment of Alzheimer’s disease: an update. Am Fam Physician 2003; 68: 1365–72
Alzheimer’s Association and National Alliance for Caregiving. Families care: Alzheimer’s caregiving in the United States 2004 [online]. Available from URL: http://www.alz.org/national/documents/report_familiescare.pdf [Accessed 2009 Feb 2]
Slattum PW, Johnson MA. Caregiver burden in Alzheimer’s disease. Consult Pharm 2004; 19: 352–62
Barat I, Andreasen F, Damsgaard EM. The consumption of drugs by 75-year-old individuals living in their own homes. Eur J Clin Pharmacol 2000; 56: 501–9
Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007; 69Suppl. 1: S4–9
Sugimoto H, Iimura Y, Yamanishi Y, et al. Syntheses and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl] piperidine hydrochloride and related compounds. J Med Chem 1995; 38: 4821–9
Rogers SL, Yamanishi Y, Yamatsu K. E2020: thepharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston (MA): Birkhauser, 1991: 314–20
Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007 Jul 31; 69(5): 459–69
Liston DR, Nielsen JA, Villalobos A, et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer’s disease. Eur J Pharmacol 2004; 486: 9–17
Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer’s disease. Br J Clin Pharmacol 2004 Nov; 58 Suppl. 1: 1–8
Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998 Jan; 50(1): 136–45
Weyer G, Erzigkeit H, Kanowski S, et al. Alzheimer’s disease assessment scale: reliability and validity in a multi-center clinical trial. Int Psychogeriatr 1997 Jun 2; 9(2): 123–38
Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004 Jun 26; 363(9427): 2105–15
Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2003; (3): CD001190
Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20
Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005; 20: 559–69
Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004; 19: 624–33
Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc 2003 Jun; 51(6): 737–44
Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007 May; 8(7): 1011–23
Gander B, Meinel M, Walter E, et al. Polymers as a platform of drug delivery: reviewing our current portfolio on poly (lactide-coglycolide)(PLGA) microspheres. Chimia 2001; 55: 212–7
Pengcheng Z, Lingli C, Wangwen G, et al. In vitro and in vivo evaluation of donepezil-sustained release micro-particles for the treatment of Alzheimer’s disease. Biomaterials 2007 Apr; 28(10): 1882–8
ClinicalTrials.gov. Comparison of 23 mg donepezil sustained release (SR) to 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer’s disease [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00478205 [Accessed 2009 Feb 2]
Harada CN, Shega JW, Sachs GA. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004 Dec 9; 351(24): 2509–18
Fratiglioni L, Grut M, Forsell Y, et al. Prevalence of Alzheimer’s disease and other dementias in an elderly urban population: relationship with age, sex and education. Neurology 1991; 41: 1886–92
Small GW, Kaufer D, Mendiondo MS, et al. Cognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005; 59: 473–7
Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer’s disease: epidemiology and management. Drugs Aging 2001; 18(11): 853–62
Cummings J, Lefèvre G, Appel-Dingemanse S, et al. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69(4 Suppl.): S10–3
Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41(10): 719–39
Spencer CM, Noble S. Rivastigmine: a review on its use in Alzheimer’s disease. Drugs Aging 1998; 13: 391–411
Polinsky RJ. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther 1998; 20: 634–47
Feldman H, Lane R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2007 Oct; 78(10): 1056–63
Exelon® patch: US prescribing information. East Hanover (NJ): Novartis, 2007 [online]. Available from URL: http://www.pharma.us.novartis.com/newsroom/press-release.jsp?PRID=2026 [Accessed 2009 Feb 2]
Lefèvre G, Pommier F, Sedek G, et al. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol 2008 Feb; 48(2): 246–52
Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69(4 Suppl. 1): S14–22
Cummings J, Lefèvre G, Small G, et al. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69: S10–3
Winblad B, Fillit H, for the IDEAL study investigators. AD caregivers prefer patches to pills [platform presentation]. Festival of International Conferences on Caregiving, Disability, Aging and Technology; 2007 Jun 16–19; Toronto (ON)
Blesa R, Ballard C, Orgogozo JM, et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007; 69(4 Suppl. 1): S23–8
Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease: rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 May; 22(5): 456–67
Olin J, Schneider L. Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev 2001; (1): CD001747
Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ 2000 Dec 9; 321(7274): 1445–9
Rockwood K, Fay S, Song X, et al. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial. CMAJ 2006; 174(8): 1099–105
Raskind MA, Peskind ER, Truyen L, et al. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004 Feb; 61(2): 252–6
Galasko D, Kershaw PR, Schneider L, et al. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer’s disease. J Am Geriatr Soc 2004 Jul; 52(7): 1070–6
Morris JC, Farlow MR, Ferris SH, et al. Therapeutic continuity in Alzheimer’s disease: switching patients to galantamine [panel discussion]: recommendations for prescribers. Clin Ther 2001; 23Suppl. A: 31
Mayor S. Regulatory authorities review use of galantamine in mild cognitive impairment [letter]. BMJ 2005 Feb 5; 330(7486): 276
Ortho-McNeil Neurologics Inc. Reminyl (galantamine hydrobromide) renamed Razadyne (galantamine hydrobromide) in U.S. to support patient safety [online]. Available from URL: http://www.jnj.com [Accessed 2006 Mar 15]
Zhao Q, Janssens L, Verhaeghe T, et al. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Curr Med Res Opin 2005 Oct; 21(10): 1547–54
Hing JP, Piotrovsky V, Kimko H, et al. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Curr Med Res Opin 2005 Apr; 21(4): 483–7
Brodaty H, Corey-Bloom J, Potocnik FC, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 20(2-3): 120–32
Suh GH, Yeon Jung H, Uk Lee C, et al. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean population. Korean Galantamine Study Group. Clin Ther 2004 Oct; 26(10): 1608–18
Robinson DM, Plosker GL. Galantamine extended release. CNS Drugs 2006; 20(8): 673–81
Dunbar F, Zhu Y, Brashear HR. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel group, 6-month study. Clin Ther 2006 Mar; 28(3): 365–72
Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 1998; 116: 331–47
Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994; 43: 91–104
Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317–24
Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41
Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–46
Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006 Jan; 63(1): 49–54
McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; (2): CD003154
Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24 week randomized, controlled trial. Memantine MEM-MD-10 Study Group. Am J Geriatr Pyschiatry 2004; 14: 704–15
Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother 2004 Dec; 2(4): 303–12
Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005 Aug 9; 65(3): 481–2
Ott BR, Blake LM, Kagan E, et al. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease. J Neurol 2007 Mar; 254(3): 351–8
Doody RS, Geldmacher DS, Gordon B, et al. Open label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427–33
Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–8
Jones R, Bayer A, Inglis F, et al. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer’s disease. Int J Geriatr Psychiatry 2007; 22: 258–62
Kornhuber J, Kennepohl EM, Bleich S, et al. Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet 2007; 46: 599–612
Van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Memantine MEM-MD-01 Study Group. Alzheimer Dis Assoc Disord 2007 Apr–Jun; 21(2): 136–43
Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98
Jones R, Bayer A, Inglis F, et al. Once-daily dosing of memantine found to be as safe and tolerable as twice-daily dosing in a 12-week, double-blind study in moderate to severe Alzheimer’s disease. Int J Geriatr Psychiatr 2007; 22: 258-62
Acknowledgements
No sources of funding were used to assist in the preparation of this review. Dr Grossberg serves as a consultant to Forest, Novartis and Pfizer Pharmaceuticals, and has received institutional research support from Forest, Novartis and Eisai/Pfizer Pharmaceuticals. Dr Bassil has no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bassil, N., Grossberg, G.T. Novel Regimens and Delivery Systems in the Pharmacological Treatment of Alzheimer’s Disease. CNS Drugs 23, 293–307 (2009). https://doi.org/10.2165/00023210-200923040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200923040-00003